OncoImmunity announced today the signing of a collaboration agreement with a European cancer vaccine company. The companies will cooperate to preclinically access the predictive capabilities of OncoImmunity's artificial intelligence platform called the ImmuneProfiler™ to identify immunogenic neoantigens in sarcoma.
The newly signed collaboration agreement adds to a growing list of European, North American and Asian companies and organisations that are using the ImmuneProfiler™ platform to identify optimal neoantigen targets.
